Capsovision (CV) closed at $6.80 on October 21, 2026, up 1.8% from the previous close, on volume of 169,625 shares (30-day average 223,251).
Data as of October 21, 2026.
CapsoVision to Present at the 20th Annual LD Micro Main Event
Globe Newswire (Tue, 13-Oct 4:05 PM ET)
CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus
Globe Newswire (Mon, 28-Sep 9:00 AM ET)
CapsoVision to Participate in Upcoming Investor Conferences
Globe Newswire (Thu, 3-Sep 4:05 PM ET)
CapsoVision Reports Second Quarter 2026 Financial Results
Globe Newswire (Thu, 13-Aug 4:05 PM ET)
CapsoVision Announces International Launch of AI Highlights
Globe Newswire (Mon, 3-Aug 4:30 PM ET)
CapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026
Globe Newswire (Thu, 30-Jul 4:05 PM ET)
Market Chameleon (Mon, 23-Mar 7:43 AM ET)
CapsoVision Inc is a commercial-stage medical technology enterprise that innovates, manufactures, and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal (GI) system. The company's core technology platform is an orally ingestible capsule including multiple cameras facilitating 360-degree imaging, light-emitting diodes for measurement, onboard memory storage, and battery life permitting recording and onboard storage of video images. CapsoVision's products consist of the on-market CapsoCam Plus, directed at the small intestines, and the in-development CapsoColon 3D, directed at the large intestines. Geographically, the company generates the majority of its revenue from the United States.
Capsovision trades on the NASDAQ stock market under the symbol CV.
As of October 21, 2026, CV stock price climbed to $6.80 with 169,625 million shares trading.
CV has a beta of -1.85, meaning it tends to be less sensitive to market movements. CV has a correlation of 0.04 to the broad based SPY ETF.
CV has a market cap of $361.83 million. This is considered a Small Cap stock.
Last quarter Capsovision reported $4 million in Revenue and -$.15 earnings per share. This fell short of revenue expectation by $-170,000 and missed earnings estimates by -$.02.
The top ETF exchange traded funds that CV belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
CV has outperformed the market in the last year with a price return of +41.4% while the SPY ETF gained +16.3%. However, in the short term, CV had mixed performance relative to the market. It has underperformed in the last 3 months, returning -3.1% vs +3.6% return in SPY. But in the last 2 weeks, CV shares have fared better than the market returning +4.0% compared to SPY -0.5%.
CV support price is $6.40 and resistance is $6.96 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CV shares will trade within this expected range on the day.